SUPPLEMENT TO PROXY STATEMENT
FOR THE 2020 ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON APRIL 23, 2020

This Supplement to the Proxy Statement (“Supplement”), dated April 7, 2020, is being made available to shareholders of Pfizer Inc. (“Pfizer” or the “Company”) on or about April 7, 2020 in connection with the solicitation of proxies by our Board of Directors (“Board”) for the Annual Meeting of Shareholders to be held on Thursday, April 23, 2020 at 9:00 a.m. Eastern Daylight Time (the “Annual Meeting”). This Supplement and the Amended Notice of 2020 Annual Meeting amend the Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on March 13, 2020.

Election of an Additional Director. This Supplement provides information related to Item 9, which has been added to the agenda for the Annual Meeting, and does not provide all of the information that is important to your decisions in voting at the Annual Meeting. Additional information is contained in the Proxy Statement for our Annual Meeting that was previously made available to our shareholders.

Virtual Annual Meeting. This Supplement also provides information related to the virtual Annual Meeting. In response to continued public health concerns related to the coronavirus / COVID-19, and to support the health and well-being of our shareholders and other meeting participants, please note that the location of the Annual Meeting has been changed and will be held in a virtual meeting format only. While you will not be able to attend the Annual Meeting at a physical location, we have designed the virtual Annual Meeting to ensure that our shareholders are given the same rights and opportunities to actively participate in the Annual Meeting as they would at an in-person meeting, using online tools to facilitate shareholder access and participation.

There is no change to the record date to determine shareholders entitled to notice of and to vote at the Annual Meeting. As such, only shareholders of record as of the close of business on February 25, 2020 are entitled to receive notice of and to vote at the virtual Annual Meeting and any adjournments or postponements thereof.

The amended proxy card or voting instruction form enclosed with this Supplement differs from the proxy card or voting instruction form previously furnished to you with the Proxy Statement dated March 13, 2020, in that the enclosed proxy card or voting instruction form includes the election of the additional Director nominee as a new Item 9. If you have already voted, we encourage you to resubmit your vote on all nine proposals by submitting the amended proxy card or voting instruction form enclosed with this Supplement or by submitting a proxy by telephone or through the Internet by following the procedures on your amended proxy card or voting instruction form. However, if you return, or have returned, an original proxy card or voting instruction form, your proxy will still remain valid for all of the other proposals and Director nominees except Dr. Desmond-Hellmann because she is not listed as a nominee on the original proxy card or voting instruction form, and will be voted at the Annual Meeting unless revoked. PLEASE NOTE THAT IF YOU SUBMIT A NEW PROXY CARD OR VOTING INSTRUCTION FORM, IT WILL REVOKE ALL PRIOR PROXY CARDS OR VOTING INSTRUCTION FORMS, SO IT IS IMPORTANT TO INDICATE YOUR VOTE ON EACH PROPOSAL ON THE NEW PROXY CARD OR VOTING INSTRUCTION FORM.

Except for the addition of Item 9 and change to a virtual meeting format, this Supplement does not modify, amend, supplement or otherwise affect any matter presented for consideration in the Proxy Statement. The Proxy Statement contains important additional information. This Supplement should only be read in conjunction with the Proxy Statement.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 23, 2020

Our proxy materials, including the Amended Notice of 2020 Annual Meeting of Shareholders, the Proxy Statement, this Supplement, the accompanying amended proxy card and the 2019 Financial Report, are available at https://investors.pfizer.com/financials/annual-reports/default.aspx. Your vote is very important. For specific instructions on how to vote your shares, please review the instructions on your proxy card or voting instruction form. Alternatively, if you attend the virtual Annual Meeting, you may also vote during the meeting. To attend the virtual Annual Meeting, please visit www.meetingcenter.io/280277443. The password for the meeting is PFE2020.

Item 9 – Election of an Additional Director

At the Annual Meeting, fourteen members of our Board are standing for re-election, to hold office until the next Annual Meeting of Shareholders.

Biographical and stock ownership information with respect to the thirteen Director nominees described in Item 1 of the Proxy Statement and certain other information relating to the Company’s Board is set forth in the Proxy Statement under the sections captioned “Item 1 — Election of Directors” and “Non-Employee Director Compensation.”

On April 1, 2020, the Board, acting upon the recommendation of the Governance & Sustainability Committee, elected Dr. Susan Desmond-Hellmann to the Board and nominated her for re-election at the 2020 Annual Meeting. The Board has nominated Dr. Desmond-Hellmann in addition to the nominees described in Item 1 of the Proxy Statement, to serve until the next Annual Meeting of Shareholders. The Governance & Sustainability Committee considered the election of Dr. Desmond-Hellmann as a Director upon recommendation by our Chairman and Chief Executive Officer and evaluation by a third-party search firm. We expect Dr. Desmond-Hellmann to be able to serve if elected. If she is not able to serve, the persons appointed by the Board and named as proxies in the proxy materials or, if applicable, their substitutes (the “Proxy Committee”) may vote their proxies for a substitute nominee, unless the Board chooses to reduce the number of Directors serving on the Board.

The Board has determined that Dr. Desmond-Hellmann is independent under our Director Qualification Standards (“Standards”). In determining that Dr. Desmond-Hellmann is independent, the Governance & Sustainability Committee and the Board took into consideration that she is a Senior Advisor to the Bill & Melinda Gates Medical Research Institute, which is affiliated with the Bill & Melinda Gates Foundation, a philanthropic organization that has supported Pfizer’s philanthropic efforts. Our Standards meet, and in some respects exceed, the independence requirements of the New York Stock Exchange.

Below is biographical and certain other information, as of the date of this Supplement, with respect to Dr. Desmond-Hellmann, including her principal occupation and business experience for the past five years. The information presented below for Dr. Desmond-Hellmann, regarding her specific experience, qualifications, attributes and skills, led the Governance & Sustainability Committee and our Board to conclude that she should be nominated as a Director nominee and is qualified to continue to serve on the Board, if elected at the Annual Meeting.

	Susan Desmond-Hellmann, M.D., M.P.H.	AGE: 62
	DIRECTOR SINCE: 2020
	BOARD COMMITTEES: Governance & Sustainability and Science and Technology
	KEY SKILLS:     Business Leadership & Operations     Medicine & Science
	Healthcare & Pharma     Academia     Technology
	OTHER CURRENT PUBLIC BOARDS: None

Served as the Chief Executive Officer of the Bill & Melinda Gates Foundation, a private foundation committed to enhancing global healthcare, reducing extreme poverty and expanding educational opportunities, from 2014 until her retirement in 2020 and currently continues as a Senior Advisor and a Board member of the Gates Medical Research Institute. Prior to joining the Bill & Melinda Gates Foundation, she served as the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF) from 2009 to 2014. Dr. Desmond-Hellmann remains an Adjunct Professor at UCSF. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development from 2005-2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, she was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute.

Director of Facebook Inc. from 2013 to 2019. Director of Procter & Gamble from 2010 to 2017.

Stock Ownership of Dr. Desmond-Hellmann

Dr. Desmond-Hellmann beneficially owned 3,408 shares of our common stock as of the close of business on January 31, 2020, the date of the stock ownership information disclosed for each of our Directors and Named Executive Officers under the section captioned “Securities Ownership” in the Proxy Statement.

Vote Required

Under our By-laws and our Corporate Governance Principles, Directors must be elected by a majority of the votes cast in uncontested elections, such as the election of Directors at the Annual Meeting. This means that the number of votes cast “for” a Director nominee must exceed the number of votes cast “against” that nominee. Abstentions and broker non-votes are not counted as votes “for” or “against” a Director nominee. Any nominee who does not receive a majority of votes cast “for” his or her election would be required to tender his or her resignation promptly following the failure to receive the required vote. Within 90 days of the certification of the shareholder vote, the Governance & Sustainability Committee would then be required to make a recommendation to the Board as to whether the Board should accept the resignation, and the Board would be required to decide whether to accept the resignation and disclose its decision-making process. In a contested election, the required vote would be a plurality of votes cast.

VOTING AND REVOCABILITY OF PROXIES

Please vote as soon as possible using the amended proxy card or voting instruction form enclosed with this Supplement which includes the election of the additional Director Nominee, Dr. Desmond-Hellmann, as a new Item 9. If you have already voted, you are not required to vote again. However, if you would like to vote for the new Item 9, Director Nominee Dr. Desmond-Hellmann, you must vote again using the amended proxy card or voting instruction form.

If you have already voted, your original proxy card or voting instruction form will remain valid for all of the other proposals on the previous ballot. Please note that if you submit a new proxy card or voting instruction form, it will revoke all prior proxy cards or voting instruction forms, so it is important to indicate your vote on each proposal on the new proxy card or voting instruction form.

If the amended proxy card or original proxy card is properly signed, dated and returned and is not revoked, the proxy will be voted at the Annual Meeting in accordance with your instructions indicated on the proxy. If no instructions are indicated on the amended proxy, the proxies will be voted (and any voting instructions to record holders will be given) “FOR” proposals 1, 2, 3 and 9 and “AGAINST” proposals 4, 5, 6, 7 and 8, and in their discretion, upon such other business as properly comes before the meeting.

You may revoke your proxy and change your vote at any time before your vote is due, including the final vote at the Annual Meeting if you have the right to vote. Attendance at the Annual Meeting will not automatically revoke your proxy unless you vote at the Annual Meeting or specifically request in writing that your prior proxy be revoked.